Home World News Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who... World News Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 410 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR David Dangoor: “Education is a treasure that you give someone and... June 14, 2021 A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... August 16, 2021 EMA Recommends Extension of Indications for Nivolumab October 20, 2020 FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer August 16, 2022 Load more HOT NEWS Husband Moved To Tears After Opening Christmas Gift From Wife A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... How CRISPR is Changing Cancer Research and Treatment EMA Recommends Granting a Marketing Authorisation for Elinzanetant
